Not logged in
Share
SaveCombination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER plus breast tumors
Carnevalli, Larissa; Ros, Susana; Urosevic, Jelena; Cureton, Natalie; Darcy, Sophie; Lawson, Mandy; Williamson, Stuart; Gutierrez, Pablo Morentin; Bashi, Azadeh; Moss, Jennifer; Morrow, Christopher; Simon, Barry; Klinowska, Teresa
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save